The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

US taxpayers spent an estimated $6 billion researching, developing, and implementing new blockbuster weight-loss drugs, ...

After the contentious Senate confirmation of Robert F. Kennedy Jr., another crucial governmental health leadership ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...